Method of treating endometreosis
The present invention relates to the treatment of a woman for endometriosis comprising the administration of IFN-gamma, a cytokine antagonist and/or an anti-estrogenic agent.
1 . A method of treating a woman suffering from or susceptible to endometriosis, comprising administering to the woman an effective amount of interferon-gamma (IFN-γ).
2 . A method of treating a woman suffering from or susceptible to endometriosis, comprising administering to the woman an effective amount of a cytokine antagonist.
3 . A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of a combination of IFN-γ and a cytokine antagonist.
4 . A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of IFN-γ in combination with an anti-estrogenic agent.
5 . A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of a cytokine antagonist in combination with an anti-estrogenic agent.
6 . A method of treating a woman suffering from or susceptible to endometriosis comprising administering a therapeutically effective amount of IFN-γ and a cytokine antagonist in combination with an anti-estrogenic agent.
7 . The method of claim 4 , wherein the anti-estrogenic agent is an aromatase inhibitor.
8 - 12 . (canceled)
13 . An article of manufacture comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises IFN-γ together with a pharmaceutical acceptable carrier
14 . An article of manufacture comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a cytokine antagonist together with a pharmaceutical acceptable carrier
15 . An article of manufacture comprising:
i) a packaging material comprising a label which indicates said pharmaceutical may be administered, for a sufficient term at an effective dose, for treating or preventing endometriosis in a woman; and
ii) a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises a combination of IFN-γ and a cytokine antagonist together with a pharmaceutical acceptable carrier
16 . The method of claim 2 , wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.
17 . The method of claims 3 , wherein the cytokine antagonist is an antagonist to tumor necrosis factor.
18 . The method of claim 5 , wherein the anti-estrogenic agent is an aromatase inhibitor.
19 . The method of claim 6 , wherein the anti-estrogenic agent is an aromatase inhibitor.
20 . The method of claims 5 , wherein the cytokine antagonist is an antagonist to tumor necrosis factor.
21 . The method of claims 6 , wherein the cytokine antagonist is an antagonist to tumor necrosis factor.
22 . The method of claim 3 , wherein the cytokine antagonist is selected from the group consisting of antagonist to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.
23 . The method of claim 5 , wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.
24 . The method of claim 6 , wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.
25 . The method of claim 14 , wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.
26 . The method of claim 15 , wherein the cytokine antagonist is selected from the group consisting of antagonists to tumor necrosis factor-related apoptosis-inducing ligand, OX40 Ligand, lymphotoxin alpha, interleukin 1 alpha, interleukin-1 beta, interleukin-6, interleukin-8, interleukin-11, leukemia inhibitory factor, Fas Ligand, oncostatin M, interferon alpha, interferon beta, insulin growth factor-1, stem cell factor and human growth hormone.